Posted On: 12/23/2016 9:13:46 AM
Post# of 23063
$BNTC low floater no reaction to news yet.
09:01 AM EST, 12/23/2016 (MT Newswires) -- Benitec Biopharma (BNTC) said pre-market Friday it sealed an agreement with NantWorks under which it will sub-license a clinical program to develop an asset to treat head and neck squamous cell carcinoma.
The company said it will develop a clinical stage program for head and neck cancers using a gene silencing approach that targets the epidermal growth factor receptor.
Price: 1.43, Change: , Percent Change:
http://www.mtnewswires.com Copyright © 2016 MTNewswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
09:01 AM EST, 12/23/2016 (MT Newswires) -- Benitec Biopharma (BNTC) said pre-market Friday it sealed an agreement with NantWorks under which it will sub-license a clinical program to develop an asset to treat head and neck squamous cell carcinoma.
The company said it will develop a clinical stage program for head and neck cancers using a gene silencing approach that targets the epidermal growth factor receptor.
Price: 1.43, Change: , Percent Change:
http://www.mtnewswires.com Copyright © 2016 MTNewswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
(0)
(0)
